AIM IP specialist Tekcapital to sell or float all four portfolio companies 'within 2 years'. Watch the full video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Share News (AVCT)

Share Price Information for Avacta (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 262.00
Bid: 260.00
Ask: 262.00
Change: 20.80 (8.62%)
Spread: 2.00 (0.77%)
Open: 245.00
High: 262.00
Low: 240.00
Yest. Close: 241.20
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

IN BRIEF: Avacta Not Involved With Medusa 19's Covid Antibody Test

Mon, 17th Aug 2020 20:07

Avacta Group PLC - Wetherby, England-based pre-clinical stage biotechnology company - States it is not involved with the development of Medusa 19's Covid-19 antibody test. Issues clarification following information appearing on the Medusa 19 website regarding a SARS-CoV-2 antibody test on Friday, adding that performance figures appearing on Medusa 19' site relate to this antibody test and do not relate to Avacta's rapid SARS-CoV-2 antigen test.

Current stock price: 145.00 pence

Year-to-date change: up more than eight-fold from 17.25p

By Ife Taiwo; ifetaiwo@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News

Avacta sees Covid-19 tests driving earnings after reporting 2020 loss

Avacta sees Covid-19 tests driving earnings after reporting 2020 loss

22 Apr 21 12:17

Avacta reports positive data for Covid-19 test product

(Sharecast News) - Diagnostics and cancer therapies developer Avacta announced positive data from the clinical validation of its 'AffiDX' SARS-CoV-2 antigen lateral flow test on Tuesday.

20 Apr 21 15:18

IN BRIEF: Avacta's rapid Covid-19 test is 98% sensitive in trial

IN BRIEF: Avacta's rapid Covid-19 test is 98% sensitive in trial

20 Apr 21 12:17

AIM WINNERS & LOSERS: Warpaint tops outlook; Avacta's Covid test works

AIM WINNERS & LOSERS: Warpaint tops outlook; Avacta's Covid test works

20 Apr 21 11:35

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

15 Apr 21 14:56

IN BRIEF: Avacta in global Affimer distribution agreement with Abcam

IN BRIEF: Avacta in global Affimer distribution agreement with Abcam

6 Apr 21 13:53

Avacta signs global distribution deal with Abcam

(Sharecast News) - Cancer therapies and diagnostics developer Avacta Group has entered into a global distribution agreement with Abcam, it announced on Tuesday, to sell its recently-developed SARS-CoV-2 research 'ELISA Affimer' reagents.

6 Apr 21 11:03

EXECUTIVE CHANGES: Ten Entertainment, Emmerson chairs step down

EXECUTIVE CHANGES: Ten Entertainment, Emmerson chairs step down

25 Mar 21 15:57

IN BRIEF: Avacta Group signs diagnostic licensing deal with Biokit

IN BRIEF: Avacta Group signs diagnostic licensing deal with Biokit

9 Mar 21 20:19

Avacta enters licence deal with Werfen subsidiary Biokit

(Sharecast News) - Cancer therapy and diagnostics developer Avacta has entered into a licence agreement with Werfen subsidiary Biokit, it announced on Tuesday, to incorporate 'Affimer' reagents into a Biokit in-vitro diagnostic product.

9 Mar 21 11:08

IN BRIEF: Avacta's Covid antigen test confirmed to detect variants

IN BRIEF: Avacta's Covid antigen test confirmed to detect variants

8 Mar 21 19:07

Avacta confirms efficacy of test on variant Covid-19 strains

(Sharecast News) - Cancer therapies and diagnostics company Avacta announced on Monday that its 'AffiDX' SARS-CoV-2 rapid antigen lateral flow test detected the dominant new variants of coronavirus, known as the B117 or 'Kent', variant, and the D614G variant, as well as the original strain.

8 Mar 21 11:06

TRADING UPDATES: Avacta Plans Covid Test Launch Near First Quarter End

TRADING UPDATES: Avacta Plans Covid Test Launch Near First Quarter End

24 Feb 21 11:45

AIM WINNERS & LOSERS: Mkango Hails Pilot Plant Processing Milestone

AIM WINNERS & LOSERS: Mkango Hails Pilot Plant Processing Milestone

24 Feb 21 10:25

AIM WINNERS & LOSERS: Clear Leisure Surges Amid Placing, Bitcoin Plans

AIM WINNERS & LOSERS: Clear Leisure Surges Amid Placing, Bitcoin Plans

22 Feb 21 11:01

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.